Enhua Pharmaceuticals: The innovative drug NH600001 emulsion injection is expected to apply for NDA this year.

On May 15th, Enhua Pharmaceuticals stated on the interactive platform that the company's innovative drug NH600001 emulsion injection has completed phase III clinical trials and is expected to apply for NDA this year, aiming to achieve market approval as soon as possible.